Skip to Content
Morningstar

Fidelity Disruptive Medicine ETF FMED

Morningstar Medalist Rating
Medalist Rating as of | See Fidelity Investment Hub

Morningstar’s Analysis FMED

Will FMED outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable FMED’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the FMED management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of FMED’s parent organization’s priorities and whether they’re in line with investors’ interests.

Fidelity Disruptive Medicine ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FMED

More FMED Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 35.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Boston Scientific Corp

6.27 3.2 Mil
Healthcare

Fidelity Securities Lending Cash Central Fund

4.50 2.3 Mil
Cash and Equivalents

UnitedHealth Group Inc

4.28 2.2 Mil
Healthcare

Danaher Corp

3.70 1.9 Mil
Healthcare

Centene Corp

3.67 1.9 Mil
Healthcare

Intuitive Surgical Inc

3.42 1.8 Mil
Healthcare

Alnylam Pharmaceuticals Inc

3.18 1.6 Mil
Healthcare

Insulet Corp

2.95 1.5 Mil
Healthcare

Penumbra Inc

2.55 1.3 Mil
Healthcare

Regeneron Pharmaceuticals Inc

2.54 1.3 Mil
Healthcare